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Sir,
We thank Dr. Mash for her interest in our findings regarding
cocaine abuse and heat shock protein 70 (HSP70) gene expres-
sion, which were recently published in this journal (1). In her
lengthy Commentary, Dr. Mash reviewed the literature on
excited delirium (ED) syndrome, cocaine effects on cerebral
vasculature, terminal hypoxia, data normalization and outlier
determination, and the intricacies of quantitative PCR. We limit
our response to a few issues meriting comment.
To place our findings in context, Mash et al. previously
reported (2) that HSP70 gene expression was elevated in the
postmortem brains of cocaine abusers who had exhibited ED
prior to death, relative to other (non-ED) cocaine fatalities and
control subjects. In the course of our recent postmortem studies
to determine the global profile of gene expression associated
with human cocaine abuse, we found that the abundance of two
HSP70-related gene transcripts was, in fact, significantly
increased in our cocaine abuse cohort as a group compared with
well-matched drug-free control subjects (1); thus, our data are
not in agreement with this earlier publication. We subsequently
sought to identify variables that might account for this unex-
pected discrepancy, as well as the variance in HSP70 transcript
abundance observed within our cocaine abuse cohort. We
determined that elevated HSP70 expression was not correlated
with cocaine or metabolite levels, but was associated with a
documented period of survival and contact with medical person-
nel and/or police between last cocaine use and death. In fact,
HSP70 transcript abundance was statistically predictive as a
diagnostic test for such a survival period (1). Behavioral
evidence of ED syndrome was clearly observed in two of our
cocaine fatalities, but these cases did not exhibit significantly
increased HSP70 expression (conversely, the subjects with the
highest HSP70 expression were not reported to exhibit ED prior
to death).
In her Commentary, Dr. Mash questioned the determination of
ED syndrome in two of our cocaine subjects. As discussed in
our study (1), the final classification of cocaine-related fatalities
was made after review of case files (police reports, medical files,
toxicology reports, and autopsy results) by a trained forensic
pathologist working in a jurisdiction with a large number of
drug-related deaths and well versed in the nuances associated
making the determination of cocaine intoxication/abuse and ED.
Some additional details regarding these ED cases were provided
during the peer-review process, but excluded from the final man-
uscript precisely so as to avoid undue emphasis on ED—as
clearly discussed (1), our conclusions about ED are tempered by
our very limited sample. Like the majority of ED cases previ-
ously studied by Mash et al. (2), our two cases did not have ED
listed as the cause of death.
Other criticisms raised regarding subject postdrug survival
time and possible cocaine-induced seizures are surprising, given
that the Mash et al. publication featured ED subjects with sur-
vival times of up to 2 days (with over one half of ED subjects
surviving at least 1 h postintervention) and a reported 13% inci-
dence of seizures prior to death (2). In our study, measures of
tissue sample quality and RNA quality for the high HSP70 sub-
jects (pH 6.5  0.2 and RNA integrity number 6.1  0.4,
respectively) did not differ from the other subjects with lower
HSP70 values (1). Furthermore, unbiased profile-wide hierarchi-
cal clustering of microarray data did not identify the cases with
high HSP70 levels as outliers (data not shown).
Putting aside these distractors, the fundamental point of our
study (1) is the finding that HSP70 gene expression was
increased in an important subset of cocaine-related fatalities
independent of ED, in contrast to the conclusion of Mash et al.
that increased HSP70 expression is seen only in ED subjects but
not other cocaine fatalities (2). Those authors concluded that
HSP70 “affords an objective measure to assess ED at autopsy”
and (along with antemortem behavior and another protein mar-
ker) “has validity for use in assigning ED as a cause of death”
(2, p. e18). The proposed use of HSP70 as a forensic tool should
be considered in light of the well-established principles of vali-
dation of a diagnostic test: 1. Sensitivity—that is, the ability to
obtain positive results (in this case, high HSP70) in essentially
all ED cases. 2. Specificity—that is, the ability to obtain uni-
formly negative results (low HSP70) in non-ED cocaine fatalities
and control subjects. 3. Selection of assay threshold—for a low
prevalence syndrome such as ED, even a low rate of false posi-
tives could result in detection of more false positive cases than
true ED cases. 4. Reproducibility across laboratories—to our
knowledge, there is no independent replication of an ED-specific
elevation in brain HSP70 expression. The discrepancies between
our data (1) and the previous report (2) indicate that, at least at
the present time, HSP70 determinations fall well short of valida-
tion as a diagnostic tool for ED.
In her Commentary, Dr. Mash calls for methodologically
sound studies and a specimen repository to support research into
ED. In fact, Dr. Mash currently serves as the Director of such a
biorepository, which measures purported ED biomarkers such as
HSP70 on a fee-for-service basis. Our group supports the contin-
ued search for, and appropriate validation of, diagnostic tests for
ED and other drug-related fatalities.
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